Travoprost patient responses revealed

Article

A recent study was unable to conclude whether intraocular penetration of travoprost 0.004% was affected by central corneal thickness (CCR), potentially explaining differences in patient response to the drug.

A recent study was unable to conclude whether intraocular penetration of travoprost 0.004% was affected by central corneal thickness (CCR), potentially explaining differences in patient response to the drug.

Dr J.M. Martinez-de-la-Casa et al., Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos, Madrid, Spain, observed 64 patients who were scheduled for cataract surgery without any additional ophthalmologic pathology.

Two hours before surgery a single drop of travoprost 0.004% was administered in the eye due for operation. AL-5848 concentration was determined by extracting a sample of aqueous humour.

They were compared to three patient groups identified by CCT measurements obtained by ultrasound pachymetry. Group 1 had a CCT 574 microns.

The results demonstrated a mean AL-5848 concentration of 3.27±2.03 in group 1, 3.27±2.44 ng/mL in Group II and 2.73±2.15ng/mL in group 3, meaning there were no significant differences between the groups.

The paper, published in the journal Eye can be read here.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.